A single dose of psilocybin might help reduce symptoms in treatment-resistant depression

Infarmed reports that the medicine in question, Svratato, is being funded for use in the hospital in adults who are contraindicated to "electroconvulsive therapy".

A single dose of psilocybin might help reduce symptoms in treatment-resistant depression

A new open-label study suggests that a single dose of psilocybin, combined with psychological support, may reduce symptoms in people with severe treatment-resistant depression. Improvements were sustained for up to 12 weeks, although effects were weaker in those with PTSD.

Calls to poison centers are up as ‘magic mushroom’ use increases, study says

The use of psilocybin — the hallucinogenic compound found in “magic mushrooms” — has increased significantly in Denver and throughout the country, driving a spike in calls to national poison control centers, a study found.

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – A first-in-kind open-label pilot study

The enduring and severe depression often suffered by Veterans causes immense suffering and is associated with high rates of suicide and disability. Th…

Medicinal product subject to medical prescription in adults with severe depression

In communication, the National Authority for Medicinal Products and Health Products informs that the medicine concerned (Savrato) is being financed, for use in the hospital environment, in adults "with major depression resistant to treatment, who have not responded to at least three different treatments with anti-depressants". According to the decision of 7 May, Sráto, in association with two other anti-depressants, may be used "with strategies …